A trading statement from online fashion group and AIM heavyweight ASOS (LON:ASC) is sure to be closely scrutinised on Tuesday.
Recently the firm, which will be posting at a time of reportedly decreasing UK consumer confidence amid the UK Brexit vote, gave analysts a detailed insight of its road-map towards its intended target of £2.5bn annual revenues within five years.
Broker Numis has repeated a 'buy' and says it expects little change to forecasts, adding that that the recent weakness in Sterling gives the group additional firepower to reinforce its international pricing position.
Numis remains confident
It remains "confident" in the group, says the broker.
For the group’s third quarter, the market is expecting an increase in the top line of around 23%, with the home UK market driving a lot of the growth and with the US market providing some extra zip.
Numis reckons EU trade to have improved, with a reduced impact from the terror attacks in France and the benefits of free returns across all territories and RoW to move into positive territory as Australia and Russia start to annualise-out weak sales/FX comps.
It has a target price of 4,600p, against a current share price of 4,294p.
In small caps, final results are on their way from the acquisitive pharma group Alliance Pharma plc (LON:APH).
On track to meet full year expectations?
At the AGM statement in April, the firm, which has a "buy and build" strategy of drugs and treatments told investors it was on track to meet its full year expectations.
Numis therefore expects continued momentum as seen in the first four months of the year.
Its business has been transformed in terms of scale by the acquisition of the healthcare products business from Sinclair Pharma late in 2015 and traders will be keen to hear more on the continuing amalgamation here.
It doubles the scale of sales and profits and takes its supply of medicines and products to over 100 countries, from 40 previously.
Numis notes: "Following Alliance Pharma’s acquisition of the Sinclair Healthcare Products business in late Dec 2015 the group has diversified away from 90% revenue exposure to the UK to 48%.
"We expect an update on the ongoing integration process and could receive insight into progress of key individual growth products such as Kelo-cote, Macushield and Hydromol.
Significant announcements expected:
Finals: Alliance Pharma plc (LON:APH), Begbies Traynor Group PLC (LON:BEG), Jaywing Plc (LON:JWNG)
Trading statement: ASOS PLC (LON:ASC), Michael Page International PLC (LON:MPI).